The method of claim 2 wherein said pharmaceutical dosage form provides a maximum blood plasma concentration (C<sub>max</sub>) within the range of about 80% to 125% of about 20 ng/mL of cyclobenzaprine HCl and an AUC<sub>0-168 </sub>within the range about 740 ng·hr/mL and a T_max within the range of 80% to 125% of about 7 hours following a single oral administration a pharmaceutical dosage form comprising 30 mg of cyclobenzaprine HCl. view more

The method of claim 3, wherein the adjusted mean ratio of said pharmaceutical dosage form comprising 30 mg of cyclobenzaprine to a pharmaceutical dosage form comprising 15 mg of cyclobenzaprine is greater than about 2 for each of AUC&lt;sub&gt;0-168 >(p<0.001), AUC_0-∞ (p<0.001), and C_max (p<0.001). view more

NA

The pharmaceutical dosage form of claim 2 wherein said pharmaceutical dosage form provides a maximum blood plasma concentration (C&lt;sub&gt;max&lt;/sub&gt;) within the range of about 80% to 125% of about 20 ng/mL of cyclobenzapnine HCl and an AUC&lt;sub&gt;0-168 range of about 80% to 125% of about 740 ng·hr/mL and a T_max within the range of 80% to 125% of about 7 hours following oral administration of a single 30 mg cyclobenzapnine HCl MR Capsule. view more

The pharmaceutical dosage form of claim 3 wherein the adjusted mean ratio of CMR 30 mg/CMR 15 mg is greater than about 2 for each of AUC&lt;sub&gt;0-168 &lt;/sub&gt;(p&lt;0.001), AUC&lt;sub&gt;0-∞ &lt;/sub&gt;(p&lt;0.001), and C&lt;sub&gt;max &lt;/sub&gt;(p&lt;0.001).